Updated safety and efficacy of durvalumab (MEDI4736), an anti-PD-L 1 antibody, in patients from a squamous cell carcinoma of the head and neck (SCCHN) expansion cohort von Segal, N.H., Ou, S.-H.I., Balmanoukian, A.S., Massarelli, E., Brahmer, J.R., Weiss, J., Schoffski, P., Antonia, S.J., Massard, C., Zandberg, D.P., Maher, C., Khleif, S., Jin, X., Rebelatto, M., Steele, K., Antal, J., Gupta, A., Spreafico, A.

Volltext

Safety and Clinical Activity of MK-3475 as Initial Therapy in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) von Balmanoukian, A.S, Rizvi, N.A, Garon, E.B, Patnaik, A, Gandhi, L, Leighl, N.B, Goldman, J.W, Eder, J.P, Johnson, E.A, Blumenschein, G.R, Gubens, M.A, Papadopoulos, K.P, Lubiniecki, G.M, Zhang, J, Niewood, M, Emancipator, K, Dolled-Filhart, M, Hanson, M.E, Hui, R

Volltext

127 Correlation of clinical activity of pembrolizumab (MK-3475) with immunohistochemical staining for programmed death-1 ligand (PD-L1) in ≥50% of tumor cells in a prospective non-... von Garon, E.G, Rizvi, N.A, Leighl, N.B, Hui, R, Eder, J.P, Patnaik, A, Aggarwal, C, Horn, L, Balmanoukian, A.S, Gubens, M.A, Felip-Font, E, Costa, E. Carceny, Soria, J.C, Ahn, M.J, Arkenau, H.T, Lee, J.S, Robinet, G, Lubiniecki, G.M, Zhang, J, Emancipator, K, Rutledge, R, Dolled-Filhart, M, Gandhi, L

Volltext

730MO First-in-human phase I study of INCAGN02390, a TIM-3 monoclonal antibody antagonist in patients with advanced malignancies von Gutierrez, M.E., Tang, S-C., Powderly, J.D., Balmanoukian, A.S., Janik, J., Hoyle, P., Wei, W., Gong, X., Hamid, O.

Volltext

742P First-in-human phase I study of INCAGN02385, a LAG-3 monoclonal antibody antagonist in patients with advanced malignancies von Powderly, J.D., Hamid, O., Gutierrez, M.E., Balmanoukian, A.S., Janik, J., Hoyle, P., Dong, Z., Wei, W., Chen, X., Bourayou, N., Horn, L.

Volltext

Epacadostat plus pembrolizumab in patients with advanced melanoma and select solid tumors: Updated phase 1 results from ECHO-202/KEYNOTE-037 von Gangadhar, T.C., Hamid, O., Smith, D.C., Bauer, T.M., Wasser, J.S., Olszanski, A.J., Luke, J.J., Balmanoukian, A.S., Kaufman, D.R., Zhao, Y., Maleski, J., Jones, M.J., Leopold, L., Gajewski, T.F.

Volltext

978P Pertuzumab plus trastuzumab (P+T) in patients (pts) with lung cancer (LC) with ERBB2 mutation (mut) or amplification (amp): Results from the Targeted Agent and Profiling Utili... von Ganti, A.K., Rothe, M., Mangat, P.K., Garrett-Mayer, E., Dib, E.G., Duvivier, H., Ahn, E., Behl, D., Borghaei, H., Balmanoukian, A.S., Gaba, A., Li, R., Osei-Boateng, K., Thota, R., O'Lone, R., Grantham, G.N., Halabi, S., Schilsky, R.L.

Volltext

Safety, clinical activity and biomarkers of atezolizumab (atezo) in advanced ovarian cancer (OC) von Infante, J.R., Braiteh, F., Emens, L.A., Balmanoukian, A.S., Oaknin, A., Wang, Y., Liu, B., Molinero, L., Fasso, M., O'Hear, C., Gordon, M.

Volltext

Phase 1/2 study of the safety and clinical activity of durvalumab in patients with non-small cell lung cancer (NSCLC) von Antonia, S.J., Brahmer, J.R., Khleif, S., Balmanoukian, A.S., Ou, S.-H.I., Gutierrez, M., Kim, D.-W., Kim, S.-W., Ahn, M.-J., Leach, J., Jamal, R., Jaeger, D., Jerusalem, G., Jin, X., Gupta, A., Antal, J., Segal, N.H.

Volltext

98P Olaparib (O) in patients (pts) with solid tumors with BRCA1/2 mutation (mut): Results from the targeted agent and profiling utilization registry (TAPUR) study von Ahn, E., Rothe, M., Mangat, P.K., Garrett-Mayer, E., Al Baghdadi, T., Baron, A.D., Krauss, J.C., Balmanoukian, A.S., Bauman, J.R., Hameed, M.K., Mileham, K.F., Thota, R., Gold, P.J., Meric-Bernstam, F., Powell, S.F., Yang, E.S., O'Lone, R., Grantham, G.N., Halabi, S., Schilsky, R.L.

Volltext

Long-Term Safety and Clinical Outcomes of Atezolizumab in Head and Neck Cancer: Phase Ia Trial Results von Bahleda, R., Braiteh, F.S., Balmanoukian, A.S., Braña, I., Hodi, F.S., Garbo, L., Liu, B., Molinero, L., O'Hear, C., Shen, X., Colevas, A.D.

Volltext

Epacadostat plus pembrolizumab in patients with advanced melanoma: Phase 1 and 2 efficacy and safety results from ECHO-202/KEYNOTE-037 von Hamid, O., Gajewski, T.F., Frankel, A.E., Bauer, T.M., Olszanski, A.J., Luke, J.J., Balmanoukian, A.S., Schmidt, E.V., Sharkey, B., Maleski, J., Jones, M.J., Gangadhar, T.C.

Volltext

Safety and Clinical Activity of MK-3475 as Initial Therapy in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC): Novel Therapies/Experimental Therapies von Balmanoukian, A.S., Rizvi, N.A., Garon, E.B., Patnaik, A., Gandhi, L., Leighl, N.B., Goldman, J.W., Eder, J.P., Johnson, E.A., Blumenschein, G.R., Gubens, M.A., Papadopoulos, K.P., Lubiniecki, G.M., Zhang, J., Niewood, M., Emancipator, K., Dolled-Filhart, M., Hanson, M.E., Hui, R.

Volltext

LBA43ANTITUMOR ACTIVITY OF PEMBROLIZUMAB (PEMBRO; MK-3475) AND CORRELATION WITH PROGRAMMED DEATH LIGAND 1 (PD-L1) EXPRESSION IN A POOLED ANALYSIS OF PATIENTS (PTS) WITH ADVANCED NO... von Garon, E.B., Gandhi, L., Rizvi, N., Hui, R., Balmanoukian, A.S., Patnaik, A., Eder, J.P., Blumenshein, G.R., Aggarwal, C., Soria, J-C., Ahn, M.A., Gubens, M.A., Ramalingam, S.S., Johnson, E., Arkenau, H., Lubiniecki, G.M., Zhang, J., Rutledge, R.Z., Emancipator, K., Leighl, N.

Volltext

Antitumor Activity of Pembrolizumab (Pembro; Mk-3475) and Correlation with Programmed Death Ligand 1 (Pd-L1) Expression in a Pooled Analysis of Patients (Pts) with Advanced Non–Sma... von Garon, E.B., Gandhi, L., Rizvi, N., Hui, R., Balmanoukian, A.S., Patnaik, A., Eder, J.P., Blumenshein, G.R., Aggarwal, C., Soria, J-C., Ahn, M.A., Gubens, M.A., Ramalingam, S.S., Johnson, E., Arkenau, H., Lubiniecki, G.M., Zhang, J., Rutledge, R.Z., Emancipator, K., Leighl, N.

Volltext